GlassScriptPhysician profile
James T Aills
NPI 1184612590
$1,754.84
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,425 · 2020: $134 · 2021: $184 · 2022: $12.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $746.73 | 2019 | |
| Sunovion Pharmaceuticals INC. | $239.04 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $169.12 | 2019-2020 | |
| Lundbeck LLC | $160.56 | 2019-2020 | |
| Allergan, INC. | $96.99 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $91.08 | 2019-2021 | |
| Abbvie INC. | $63.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $55.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $29.31 | 2021 | |
| Eisai INC. | $20.67 | 2021 | |
| Alkermes, INC. | $19.48 | 2021 | |
| Validus Pharmaceuticals LLC | $16.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Aills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.